Close

Eli Lilly & Co. (LLY) Announces Abemaciclib neoMONARCH Phase 2 Met Primary Endpoint

December 8, 2016 8:33 AM EST Send to a Friend
Eli Lilly and Company (NYSE: LLY) announced that the neoMONARCH study of abemaciclib, a cyclin-dependent kinase (CDK) 4 and CDK ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login